Vertex Pharma (VRTX) Tops Q3 EPS by 23c, provides guidance
Tweet
Share
E-mail
Get Alerts VRTX Hot Sheet
Price: $556.75 +1.66%
Revenue Growth %: +10.7%
Financial Fact:
Sales, general and administrative expenses: 106.06M
Today's EPS Names:
RCBC, GASS, YSG, More
Revenue Growth %: +10.7%
Financial Fact:
Sales, general and administrative expenses: 106.06M
Today's EPS Names:
RCBC, GASS, YSG, More
Join SI Premium – FREE
Vertex Pharma (NASDAQ: VRTX) reported Q3 EPS of $4.80, $0.23 better than the analyst estimate of $4.57. Revenue for the quarter came in at $3.08 billion versus the consensus estimate of $3.05 billion.
GUIDANCE:
Vertex Pharma sees FY2025 revenue of $11.9-12 billion, versus the consensus of $12.002 billion.
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Methode Electronics (MEI) Tops Q1 EPS by 2c; offers guidance
- Hewlett Packard Enterprise (HPE) Tops Q3 EPS by 19c; raises guidance
- Barrick Mining said to delay IPO of American gold business to 2027
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
